参考文献
1. 中国药典2020版四部通则9306 遗传毒性杂质控制指导原则.
2. ICH Harmonised Guideline: Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk(R1).2017.
3. Andrew Teasdale, et al. Genotoxic impurities strategies for identification and control. John Wiley & Sons, Inc.,2010.
4. Romualdo Benigni, et al.Mechanisms of chemical carcinogenicity and mutagenicity:A review with implications for predictive toxicology. Chemical Reviews 2011;111:2507-2536.
5. ICH Harmonised Guideline: Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk(R1), Questions and Answers. 2020.Version 29.
6. ICH Harmonised Guideline: Guidance on genotoxicity testing and data interpretation for pharmaceuticals intended for human use(R1).2011.
7. FDA Guidance for industry: Control of nitrosamine impurities in human drugs.2020.
8. David W. Gaylor, et al. Quick estimate of the regulatory virtually safe dose based on the maximum tolerated dose for rodent bioassays. Regulatory Toxicology and Pharmacology 1995; 22:57-63.
9. Charles Sawyer, et al. Calculation of carcinogenic potency from long term animal carcinogenesis experiments. Biometrics 1984; 40:27-40.
10. Active Pharmaceutical Ingredients Committee (APIC). Guidance on aspects of cleaning validation in active pharmaceutical ingredient plants. 2016.
11. D.W.Layton, et al. Deriving allowable daily intakes for systemic toxicants lacking chronic toxicity data. Regulatory toxicology and pharmacology 1987; 7:96-112.
12. Nevenka Kragelj Lapanja, et al. Theoretical purge factor determination as a control strategy for potential mutagenic impurities in the synthesis of drug substances. Acta Chimica Slovenica 2017; 64:1-14.
13. Romualdo Benigni, et al. Development of structural alerts for the in vivo micronucleus assay in rodents. JRC Scientific and Technical Reports 2009.